Presentations , September 15-16 2023

CLICK TO VIEW

Opening Introduction to the meeting - Ryan Fitzpatrick, CEO, MD Education

Session I: Mutations and Classification of MPN and MDS

CLICK TO VIEW
Steffen Koschmieder

CHIP and MPN,

Steffen Koschmieder, RWTH Aachen University, Germany

Interview
CLICK TO VIEW
Shlush Liran

CHIP and MDS,

Liran Shlush, Weizmann Institute of Science, Israel

CLICK TO VIEW
15. Alessandro Vannucchi

ICC vs WHO for MPN,

Alessandro M. Vannucchi, University of Florence, Italy

Interview
CLICK TO VIEW
Maria Teresa Voso

ICC vs WHO for MDS,

Maria Teresa Voso, UOSD Diagnostica Avanzata Oncoematologica del Policlinico di Tor Vergata (PTV), Italy

Interview
CLICK TO VIEW

Panel Discussion

Session II: Polycythemia vera (PV)

CLICK TO VIEW
Marie Francis Mc Mullin

Debate I: Standard of care for low-risk PV: Phlebotomy,

Mary Frances McMullin, Queen’s University Belfast, Ireland

CLICK TO VIEW
Tiziano Barbui

Standard of care for low-risk PV: Interferon,

Tiziano Barbui, University of Bergamo, Italy

Interview
CLICK TO VIEW

Panel Discussion

CLICK TO VIEW
Heinz Gisslinger

Debate II: Standard of care for high-risk PV: Interferon,

Heinz Gisslinger, Medical University of Vienna, Austria

Interview
CLICK TO VIEW
Rajko Kušec

Standard of care for high-risk PV: Hydroxyurea/ruxolitinib,

Rajko Kušec, University hospital Dubrava Zagreb, Croatia

CLICK TO VIEW

Panel Discussion

CLICK TO VIEW

Independent Medical Education Symposium supported by GSK

Session III: Essential Thrombocytopenia (ET) and special situations

CLICK TO VIEW
Paola Guglielmelli

What is “high-risk” ET? Current and future therapies,

Paola Guglielmelli, University of Florence, Italy

CLICK TO VIEW
Martin Griesshammer

Pregnancy in MPN: State of the art management,

Martin Griesshammer, Ruhr-Universität Bochum, Germany

Interview
CLICK TO VIEW
Jean-Jacques Kiladjian

MPN and SVT: Diagnosis and management,

Jean-Jacques Kiladjian, Université Paris Cité, France

Interview
CLICK TO VIEW

Panel Discussion

Session IV: Myelofibrosis (MF)

CLICK TO VIEW
Lucia Masarova

Management of early/prefibrotic MF: Does early intervention matter?,

Lucia Masarova , MD Anderson Cancer Center, USA

Interview
CLICK TO VIEW
Paola Guglielmelli

Cytopenic MF: emerging area for novel approaches,

Paola Guglielmelli, Univerisity of Florence, Italy

CLICK TO VIEW
15. Alessandro Vannucchi

First line therapy for Int2/High risk MF: where is the field going?,

Alessandro Vannucchi, University of Florence, Italy

Interview
CLICK TO VIEW

Panel Discussion

Session V: Other MPNs and Overlap Syndromes

CLICK TO VIEW
deepti-radia

Aggressive systemic mastocytosis: emerging therapeutic options,

Deepti Radia, Guy’s and St. Thomas’ NHS Foundation Trust, UK

CLICK TO VIEW
1. Andreas Reiter

Eosinophilic neoplasms: emerging therapeutic options,

Andreas Reiter, University Medical Centre Mannheim, Germany

CLICK TO VIEW
Donald P McLornan

Myeloproliferative Neoplasm-Unclassifiable (MPN-U),

Donal P McLornan, University College London Hospitals NHS Trust, UK

CLICK TO VIEW
Elias-Jabbour-crop.jpeg

CML the paradigm for MPN,

Elias Jabbour, MD Anderson Cancer Center, USA

Interview
CLICK TO VIEW

Panel Discussion

Session VI: Other MPNs and Overlap Syndromes (cont.)

CLICK TO VIEW
Michael Savona

Clinical trials in MDS/MPN: How Can we stand alone,

Michael Savona, Vanderbilt University, Nashville, USA

CLICK TO VIEW
Andrew Kuykendall

Diagnosis and management of MDS/MPN-U,

Andrew Kuykendall, Moffitt Cancer Center, Florida, USA

Interview
CLICK TO VIEW
Eric Solary

An update on CMML,

Eric Solary, Université Paris-Saclay, France

CLICK TO VIEW

Panel Discussion

Session VII: Hematopoietic stem cell transplantation (HSCT)

CLICK TO VIEW
Ruben Mesa

Debate: HSCT for MF: Earlier?,

Ruben Mesa, Wake Forest University in Winston-Salem, USA

Interview
CLICK TO VIEW
Ibrahim Yakoub-Agha

Debate: HSCT for MF: Later?,

Ibrahim Yakoub-Agha, Lille University Hospital, Lille, France

Interview
CLICK TO VIEW

Panel discussion

CLICK TO VIEW
Matteo Della Porta

Debate: HSCT for MDS: Earlier?,

Matteo Della Porta, Humanitas University, Italy

Interview
CLICK TO VIEW
Valerie Santini

Debate: HSCT for MDS: Later?,

Valeria Santini, University of Florence, Italy

Interview
CLICK TO VIEW
Marlijn-Verwimp-Hoeks

Management of iron overload in MDS: who, when?,

Marlijn Hoeks, Radboud University Medical Centre (Radboudumc), Netherlands

CLICK TO VIEW

Panel discussion

Session VIII: Myelodysplastic Syndromes (MDS)

CLICK TO VIEW
Thomas Clazeua

Standard and new drugs in higher risk MDS,

Thomas Clazeua, Centre Hospitalier Universitaire de Nice, France

Interview
CLICK TO VIEW
Malcovati, Luca

Anemia in MDS and SF3B1 mutated MDS,

Luca Malcovati, IRCCS S. Matteo Hospital Foundation & University of Pavia, Italy

Interview
CLICK TO VIEW
19. Rami Komrokji (1)

Standard and New drugs in low-risk MDS,

Rami Komrokji, MD Anderson Cancer Center, USA

CLICK TO VIEW
Lucia Messingerova

The resistance to treatment especially hypomethylating agents,

Lucia Messingerova, Slovak Academy of Sciences, Slovakia

CLICK TO VIEW
Naval Daver

Managing secondary AML: from MDS and MPN,

Naval Daver, MD Anderson Cancer Center, USA

Interview
CLICK TO VIEW

Panel discussion

It is our pleasure to invite you to participate in this one-of-a-kind event.

If you need additional information please contact us at:

office@md-education.com

MD Education Ltd
4/4a Bloomsbury Square,
London, WC1A 2RP

MD Education USA LLC
4600 140th Avenue North, Suite 180,
Clearwater, Florida 33762

Mary Frances Mc Mullin, MD

Queen’s University Belfast, Ireland

Professor Mary Frances McMullin   trained in Haematology in N. Ireland and The Royal Postgraduate Medical School, Hammersmith hospital, London. She was appointed senior lecturer in haematology in QUB in 1991 and consultant haematologist and   proceeded to Professor of Haematology in 2006. Her clinical and research interests include myeloproliferative neoplasms, investigation of the rare congenital erythrocytosis, and acute myeloid leukaemia. She now has over 250 peer reviewed publications in the area.

Paola Guglielmelli, MD

Univerisity of Florence, Italy

Paola Guglielmelli, MD, PhD
CRIMM- Center of Research and Innovation for MPN- Azienda Ospedaliera
Universitaria Careggi. University of Florence, Italy

I graduated in Medicine at the University of Florence in 2003. I got my Specialty Degree in Hematology in 2007. In 2010 Post-doctoral degree at the School in Clinical and Experimental Oncology at the University of Florence. In 2018 Associate Professor in Hematology, and from 2021: Director, Centre for Research and Innovation of Myeloproliferative Neoplasms (CRIMM), AOU Careggi-Florence.
My main scientific interests concern experimental and clinical issues of myeloproliferative disorders.
I have been working on the molecular characterization in hematopoietic progenitors of patients with MPNs and I have more recently developed novel integrated clinical-molecular prognostic models in MPN patisnts. I have been also involved in the study of a novel animal model of myelofibrosis.
Current areas of research include preclinical studies on JAK-STAT pathway, PI3K/Akt/mTOR pathway and calreticulin as a therapeutic target in myeloproliferative neoplasms, coding and not- coding RNA expression profile, exome and RNA sequencing. Furthermore, I am strongly committed to clinical work, having in routine charge patients with MPNs and being involved in clinical protocols with novel drugs and in epidemiologic studies. Since 2015, I ‘m contributing to the development of advanced molecular methodologies for the research and quantification of the most common mutations in MPN, mastocytosis, eosinophilias and mutational anomalies associated with erythrocytosis, platelet or familial platelet disorders. From 18/5/2020 the laboratory has carried out first and second level molecular tests for acute myeloid leukemia. Author of 261 publications on international scientific journals (ISI h-index=63 and proceedings of national and international conferences.

Ruben Mesa, MD,

Wake Forest University in Winston-Salem, USA

Ruben Mesa, MD, FACP recently began his tenure leading the mission and programs against cancer across Atrium Health and Atrium Health Wake Forest Baptist with the joint roles of President, Enterprise Cancer Service Line Atrium Health; Enterprise Senior Vice President for Atrium Health; Executive Director of the NCI Comprehensive Cancer based at Wake Forest Baptist; and Vice Dean for cancer programs at Wake Forest School of Medicine. In these roles Dr. Mesa oversees all efforts related to cancer practice, research and education across Atrium Health as a system including Wake Forest Baptist, Levine Cancer Institute, and all regional sites.
Dr. Mesa previously was the Executive Director of the NCI Designated Mays Cancer Center at UT Health San Antonio MD Anderson from 2017-2023 where he developed and grew the cancer service line, co-led the development and construction of a new cancer focused hospital, grew cancer faculty, peer reviewed funded research and successful renewed the NCI designation in 2020. Earlier in his career Dr Mesa practiced hematology at Mayo Clinic (MN 2002-2009, and Arizona (2009-2017)) where he was Chair of Hematology & Medical Oncology and Deputy Director of the Mayo Clinic Comprehensive Cancer Center.

Luca Malcovati, MD

IRCCS S. Matteo Hospital Foundation & University of Pavia, Italy

Dr. Lucia Messingerova has been working in the field of research on resistance to
hemato-oncological treatment since 2010, when during her PhD. studies she focused on the function of ABC transporters in the reduction of cytotoxic effect of different substances on leukemic cell lines. During her doctoral studies, she got a fellowship at the prestigious Sidney Kimmel Comprehensive Cancer Centre at Johns Hopkins Hospital, USA. After completing her studies, she started to work at the Slovak University of Technology, Faculty of Chemical and Food Technology, as well as at the Slovak Academy of Sciences in the Centre for Biosciences, where she leads a team dealing with the development of resistance to hypomethylating agents used to treat patients with myelodysplastic syndromes and acute myeloid leukemia. Currently, she also works as an alternanting representative of Slovakia in Sub-Group on Cancer under the Steering Group on Health Promotion, Disease Prevention and Management of Non- Communicable Diseases.

Lucia Messingerova, MD

Slovak Academy of Sciences, Slovakia

Dr. Lucia Messingerova has been working in the field of research on resistance to
hemato-oncological treatment since 2010, when during her PhD. studies she focused on the function of ABC transporters in the reduction of cytotoxic effect of different substances on leukemic cell lines. During her doctoral studies, she got a fellowship at the prestigious Sidney Kimmel Comprehensive Cancer Centre at Johns Hopkins Hospital, USA. After completing her studies, she started to work at the Slovak University of Technology, Faculty of Chemical and Food Technology, as well as at the Slovak Academy of Sciences in the Centre for Biosciences, where she leads a team dealing with the development of resistance to hypomethylating agents used to treat patients with myelodysplastic syndromes and acute myeloid leukemia. Currently, she also works as an alternanting representative of Slovakia in Sub-Group on Cancer under the Steering Group on Health Promotion, Disease Prevention and Management of Non- Communicable Diseases.